The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Transgenic animal bioreactors
Open accessAbstract
The production of recombinant proteins is one of the major successes of biotechnology. Animal cells are required to synthesize proteins with the appropriate post-translational modifications. Transgenic animals are being used for this purpose. Milk, egg white, blood, urine, seminal plasma and silk worm cocoon from transgenic animals are candidates to be the source of recombinant proteins at an industrial scale. Although the first recombinant protein produced by transgenic animals is expected to be in the market in 2000, a certain number of technical problems remain to be solved before the various systems are optimized. Although the generation of transgenic farm animals has become recently easier mainly with the technique of animal cloning using transfected somatic cells as nuclear donor, this point remains a limitation as far as cost is concerned. Numerous experiments carried out for the last 15 years have shown that the expression of the transgene is predictable only to a limited extent. This is clearly due to the fact that the expression vectors are not constructed in an appropriate manner. This undoubtedly comes from the fact that all the signals contained in genes have not yet been identified. Gene constructions thus result sometime in poorly functional expression vectors. One possibility consists in using long genomic DNA fragments contained in YAC or BAC vectors. The other relies on the identification of the major important elements required to obtain a satisfactory transgene expression. These elements include essentially gene insulators, chromatin openers, matrix attached regions, enhancers and introns. A certain number of proteins having complex structures (formed by several subunits, being glycosylated, cleaved, carboxylated...) have been obtained at levels sufficient for an industrial exploitation. In other cases, the mammary cellular machinery seems insufficient to promote all the post-translational modifications. The addition of genes coding for enzymes involved in protein maturation has been envisaged and successfully performed in one case. Furin gene expressed specifically in the mammary gland proved to able to cleave native human protein C with good efficiency. In a certain number of cases, the recombinant proteins produced in milk have deleterious effects on the mammary gland function or in the animals themselves. This comes independently from ectopic expression of the transgenes and from the transfer of the recombinant proteins from milk to blood. One possibility to eliminate or reduce these side-effects may be to use systems inducible by an exogenous molecule such as tetracycline allowing the transgene to be expressed only during lactation and strictly in the mammary gland. The purification of recombinant proteins from milk is generally not particularly difficult. This may not be the case, however, when the endogenous proteins such as serum albumin or antibodies are abundantly present in milk. This problem may be still more crucial if proteins are produced in blood. Among the biological contaminants potentially present in the recombinant proteins prepared from transgenic animals, prions are certainly those raising the major concern. The selection of animals chosen to generate transgenics on one hand and the elimination of the potentially contaminated animals, thanks to recently defined quite sensitive tests may reduce the risk to an extremely low level. The available techniques to produce pharmaceutical proteins in milk can be used as well to optimize milk composition of farm animals, to add nutriceuticals in milk and potentially to reduce or even eliminate some mammary infectious diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Repeat-induced gene silencing in mammals
Garrick, D., Fiering, S., Martin, D. I. K., & Whitelaw, E. (1998) · Nature Genetics · doi:10.1038/ng0198-56 · Cited by 887 · cited 1×
“A transgene seems to have less chance to be expressed efficiently if it contains non animal sequences, if it is devoid of intron and if it is integrated in multicopy (Dorer, 1997; Garrick et al., 1998).”
Background
Cited by
Humans as the World's Greatest Evolutionary Force
Palumbi, S. R. (2001) · Science · doi:10.1126/science.293.5536.1786 · Cited by 1,290
The production of recombinant pharmaceutical proteins in plants
Ma, J. K.-C., Drake, P. M. W., & Christou, P. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1177 · Cited by 960
Recombinant collagen and gelatin for drug delivery
Olsen, D. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.08.008 · Cited by 506
Yin, J., Li, G., Ren, X., & Herrler, G. (2007) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.07.012 · Cited by 373
Production of pharmaceutical proteins by transgenic animals
Houdebine, L.-M. (2009) · Comparative Immunology, Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2007.11.005 · Cited by 335
Self-citation
Metadata
- Authors
- Houdebine, L. M.
- Venue
- Transgenic Research
- Published
- 2000-08
- Volume
- 9
- Issue
- 4-5
- Pages
- 305-320
- ISSN
- 0962-8819 (ISSN-L)
- 1573-9368
- OpenAlex
- W1539409018
- Cited by
- 255
- References
- 1
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transgenic animal bioreactors. https://app.cochat.ai/papers/10.1023/a:1008934912555
- The paper
- Houdebine, L. M. (2000). Transgenic animal bioreactors. Transgenic Research. https://doi.org/10.1023/a%3A1008934912555
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.